{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T07:44:49Z","timestamp":1768549489226,"version":"3.49.0"},"reference-count":91,"publisher":"Walter de Gruyter GmbH","issue":"1","license":[{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T00:00:00Z","timestamp":1631750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch. Immunol. Ther. Exp."],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1007\/s00005-021-00630-9","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T12:02:48Z","timestamp":1631793768000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Are Host Defense Peptides and Their Derivatives Ready to be Part of the Treatment of the Next Coronavirus Pandemic?"],"prefix":"10.2478","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1521-1519","authenticated-orcid":false,"given":"Bruno","family":"Rivas-Santiago","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2174-6277","authenticated-orcid":false,"given":"Yolanda","family":"Jacobo-Delgado","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3514-5299","authenticated-orcid":false,"given":"Adrian","family":"Rodriguez-Carlos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2021,9,16]]},"reference":[{"key":"630_CR1","doi-asserted-by":"publisher","first-page":"704","DOI":"10.3390\/v11080704","volume":"11","author":"A Ahmed","year":"2019","unstructured":"Ahmed A, Siman-Tov G, Hall G et al (2019) Human antimicrobial peptides as therapeutics for viral infections. Viruses 11:704. https:\/\/doi.org\/10.3390\/v11080704","journal-title":"Viruses"},{"key":"630_CR2","doi-asserted-by":"publisher","first-page":"271","DOI":"10.3390\/v13020271","volume":"13","author":"A Bakovic","year":"2021","unstructured":"Bakovic A, Risner K, Bhalla N et al (2021) Brilacidin demonstrates inhibition of SARS-CoV-2 in cell culture. Viruses 13:271. https:\/\/doi.org\/10.3390\/v13020271","journal-title":"Viruses"},{"key":"630_CR3","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0025333","volume":"6","author":"P Barlow","year":"2011","unstructured":"Barlow P, Svoboda P, Mackellar A et al (2011) Antiviral activity and increased host defense against influenza infection elicited by the human cathelicidin LL-37. PLoS ONE 6:e25333. https:\/\/doi.org\/10.1371\/journal.pone.0025333","journal-title":"PLoS ONE"},{"key":"630_CR4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/s0167-0115(01)00282-8","volume":"101","author":"A Bastian","year":"2001","unstructured":"Bastian A, Schafer H (2001) Human alpha-defensin 1 (HNP-1) inhibits adenoviral infection in vitro. Regul Pept 101:157\u2013161. https:\/\/doi.org\/10.1016\/s0167-0115(01)00282-8","journal-title":"Regul Pept"},{"key":"630_CR5","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.jcv.2010.12.006","volume":"50","author":"J Beard","year":"2011","unstructured":"Beard J, Bearden A, Striker R (2011) Vitamin D and the anti-viral state. J Clin Virol 50:194\u2013200. https:\/\/doi.org\/10.1016\/j.jcv.2010.12.006","journal-title":"J Clin Virol"},{"key":"630_CR6","doi-asserted-by":"publisher","unstructured":"Bestle D, Heindl MR, Limburg H et al (2020) TMPRSS2 and furin are both essential for proteolytic activation of SARS-CoV-2 in human airway cells. Life Sci Alliance 3:e202000786. https:\/\/doi.org\/10.26508\/lsa.202000786","DOI":"10.26508\/lsa.202000786"},{"key":"630_CR7","doi-asserted-by":"publisher","first-page":"2377","DOI":"10.3390\/cells9112377","volume":"9","author":"D Bojkova","year":"2020","unstructured":"Bojkova D, Bechtel M, McLaughlin KM et al (2020) Aprotinin inhibits SARS-CoV-2 replication. Cells 9:2377. https:\/\/doi.org\/10.3390\/cells9112377","journal-title":"Cells"},{"key":"630_CR8","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2019.154913","volume":"126","author":"B Bongiovanni","year":"2020","unstructured":"Bongiovanni B, Marin-Luevano S, D\u2019Attilio L et al (2020) Evidence that changes in antimicrobial peptides during tuberculosis are related to disease severity, clinical presentation, specific therapy and levels of immune-endocrine mediators. Cytokine 126:154913. https:\/\/doi.org\/10.1016\/j.cyto.2019.154913","journal-title":"Cytokine"},{"key":"630_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/3-540-26765-4_1","volume":"287","author":"D Brian","year":"2005","unstructured":"Brian D, Baric R (2005) Coronavirus genome structure and replication. Curr Top Microbiol Immunol 287:1\u201330. https:\/\/doi.org\/10.1007\/3-540-26765-4_1","journal-title":"Curr Top Microbiol Immunol"},{"key":"630_CR10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41591-020-01202-8","volume":"27","author":"P Brodin","year":"2021","unstructured":"Brodin P (2021) Immune determinants of COVID-19 disease presentation and severity. Nat Med 27:28\u201333. https:\/\/doi.org\/10.1038\/s41591-020-01202-8","journal-title":"Nat Med"},{"key":"630_CR11","doi-asserted-by":"publisher","first-page":"4350","DOI":"10.1073\/pnas.1601831113","volume":"113","author":"M Brook","year":"2016","unstructured":"Brook M, Tomlinson GH, Miles K et al (2016) Neutrophil-derived alpha defensins control inflammation by inhibiting macrophage mRNA translation. Proc Natl Acad Sci USA 113:4350\u20134355. https:\/\/doi.org\/10.1073\/pnas.1601831113","journal-title":"Proc Natl Acad Sci USA"},{"key":"630_CR12","unstructured":"CDC (2003) Revised U.S. surveillance case definition for severe acute respiratory syndrome (SARS) and update on SARS cases--United States and worldwide, December 2003. MMWR Morb Mortal Wkly Rep 52:1202\u20131206. https:\/\/pubmed.ncbi.nlm.nih.gov\/14668711\/"},{"key":"630_CR13","doi-asserted-by":"publisher","first-page":"106118","DOI":"10.1016\/j.ijantimicag.2020.106118","volume":"56","author":"R Chang","year":"2020","unstructured":"Chang R, Ng TB, Sun WZ (2020) Lactoferrin as potential preventative and adjunct treatment for COVID-19. Int J Antimicrob Agen 56:106118. https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106118","journal-title":"Int J Antimicrob Agen"},{"key":"630_CR14","doi-asserted-by":"publisher","first-page":"287","DOI":"10.4149\/av_2018_222","volume":"62","author":"W Chen","year":"2018","unstructured":"Chen W, Liu Z, Zhang Q et al (2018) Induction and antiviral activity of human \u03b2-defensin 3 in intestinal cells with picornavirus infection. Acta Virol 62:287\u2013293. https:\/\/doi.org\/10.4149\/av_2018_222","journal-title":"Acta Virol"},{"key":"630_CR15","doi-asserted-by":"publisher","first-page":"1068","DOI":"10.1128\/JVI.60.3.1068-1074.1986","volume":"60","author":"K Daher","year":"1986","unstructured":"Daher K, Selsted M, Lehrer R (1986) Direct inactivation of viruses by human granulocyte defensins. J Virol 60:1068\u20131074. https:\/\/doi.org\/10.1128\/JVI.60.3.1068-1074.1986","journal-title":"J Virol"},{"key":"630_CR16","doi-asserted-by":"publisher","first-page":"7878","DOI":"10.4049\/jimmunol.0804049","volume":"182","author":"M Doss","year":"2009","unstructured":"Doss M, White M, Tecle T et al (2009) Interactions of alpha-, beta-, and theta-defensins with influenza A virus and surfactant protein D. J Immunol 182:7878\u20137887. https:\/\/doi.org\/10.4049\/jimmunol.0804049","journal-title":"J Immunol"},{"key":"630_CR17","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1021\/acsptsci.0c00059","volume":"3","author":"S Elnagdy","year":"2020","unstructured":"Elnagdy S, AlKhazindar M (2020) The potential of antimicrobial peptides as an antiviral therapy against COVID-19. ACS Pharmacol Transl Sci 3:780\u2013782. https:\/\/doi.org\/10.1021\/acsptsci.0c00059","journal-title":"ACS Pharmacol Transl Sci"},{"key":"630_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsbmb.2020.105751","volume":"203","author":"M Entrenas-Castillo","year":"2020","unstructured":"Entrenas-Castillo M, Entrenas-Costa LM, Vaquero-Barrios JM et al (2020) Effect of calcifediol treatment and best available therapy versus best available therapy on intensive care unit admission and mortality among patients hospitalized for COVID-19: A pilot randomized clinical study. J Steroid Biochem Mol Biol 203:105751. https:\/\/doi.org\/10.1016\/j.jsbmb.2020.105751","journal-title":"J Steroid Biochem Mol Biol"},{"key":"630_CR19","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s43440-020-00190-3","volume":"73","author":"N Fabisiak","year":"2021","unstructured":"Fabisiak N, Fabisiak A, Chmielowiec-Korzeniowska A et al (2021) Anti-inflammatory and antibacterial effects of human cathelicidin active fragment KR-12 in the mouse models of colitis: a novel potential therapy of inflammatory bowel diseases. Pharmacol Rep 73:163\u2013171. https:\/\/doi.org\/10.1007\/s43440-020-00190-3","journal-title":"Pharmacol Rep"},{"key":"630_CR20","doi-asserted-by":"publisher","unstructured":"Ganesh B, Rajakumar T, Malathi M et al (2021) Epidemiology and pathobiology of SARS-CoV-2 (COVID-19) in comparison with SARS, MERS: An updated overview of current knowledge and future perspectives Clin Epidemiol Global Health 10:100694. https:\/\/doi.org\/10.1016\/j.cegh.2020.100694","DOI":"10.1016\/j.cegh.2020.100694"},{"key":"630_CR21","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.610024","volume":"11","author":"R Garcia-Fandino","year":"2021","unstructured":"Garcia-Fandino R, Pineiro A (2021) Delving into the origin of destructive inflammation in COVID-19: A betrayal of natural host defense peptides? Front Immunol 11:610024. https:\/\/doi.org\/10.3389\/fimmu.2020.610024","journal-title":"Front Immunol"},{"key":"630_CR22","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1080\/02713680590934111","volume":"30","author":"J Gordon","year":"2005","unstructured":"Gordon J, Huang L, Romanowski E et al (2005) Human cathelicidin (LL-37), a multifunctional peptide, is expressed by ocular surface epithelia and has potent antibacterial and antiviral activity. Curr Eye Res 30:385\u2013394. https:\/\/doi.org\/10.1080\/02713680590934111","journal-title":"Curr Eye Res"},{"key":"630_CR23","doi-asserted-by":"publisher","first-page":"24554","DOI":"10.1074\/jbc.M112.354068","volume":"287","author":"A Gounder","year":"2012","unstructured":"Gounder A, Wiens M, Wilson S et al (2012) Critical determinants of human \u03b1-defensin 5 activity against non-enveloped viruses. J Biol Chem 287:24554\u201324562. https:\/\/doi.org\/10.1074\/jbc.M112.354068","journal-title":"J Biol Chem"},{"key":"630_CR24","doi-asserted-by":"publisher","first-page":"988","DOI":"10.3390\/nu12040988","volume":"12","author":"W Grant","year":"2020","unstructured":"Grant W, Lahore H, McDonnell S, S, et al (2020a) Evidence that vitamin D supplementation could reduce risk of influenza and COVID-19 infections and deaths. Nutrients 12:988. https:\/\/doi.org\/10.3390\/nu12040988","journal-title":"Nutrients"},{"key":"630_CR25","doi-asserted-by":"publisher","first-page":"3741","DOI":"10.3390\/nu12123741","volume":"12","author":"W Grant","year":"2020","unstructured":"Grant W, Lahore H, Rockwell M (2020b) The benefits of vitamin D supplementation for athletes: better performance and reduced risk of COVID-19. Nutrients 12:3741. https:\/\/doi.org\/10.3390\/nu12123741","journal-title":"Nutrients"},{"key":"630_CR26","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1089\/10430349950018355","volume":"10","author":"R Gropp","year":"1999","unstructured":"Gropp R, Frye M, Wagner T et al (1999) Epithelial defensins impair adenoviral infection: implication for adenovirus-mediated gene therapy. Hum Gene Ther 10:957\u2013964. https:\/\/doi.org\/10.1089\/10430349950018355","journal-title":"Hum Gene Ther"},{"issue":"suppl 1","key":"630_CR27","first-page":"6","volume":"28","author":"M Halaji","year":"2020","unstructured":"Halaji M, Farahani A, Ranjbar R et al (2020) Emerging coronaviruses: first SARS, second MERS and third SARS-CoV-2: epidemiological updates of COVID-19. Infez Med 28(suppl 1):6\u201317","journal-title":"Infez Med"},{"key":"630_CR28","doi-asserted-by":"publisher","first-page":"11126","DOI":"10.1074\/jbc.M800200200","volume":"283","author":"Y He","year":"2008","unstructured":"He Y, Xiao Y, Song H et al (2008) Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem 283:11126\u201311134. https:\/\/doi.org\/10.1074\/jbc.M800200200","journal-title":"J Biol Chem"},{"key":"630_CR29","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.3389\/fimmu.2018.01871","volume":"9","author":"M Hemshekhar","year":"2018","unstructured":"Hemshekhar M, Choi KG, Mookherjee N (2018) Host defense peptide LL-37-mediated chemoattractant properties, but not anti-inflammatory cytokine IL-1RA production, is selectively controlled by Cdc42 Rho GTPase via G protein-coupled receptors and JNK mitogen-activated protein kinase. Front Immunol 9:1871. https:\/\/doi.org\/10.3389\/fimmu.2018.01871","journal-title":"Front Immunol"},{"key":"630_CR30","doi-asserted-by":"publisher","unstructured":"Idris M, Banu S, Siva A et al (2020) Downregulation of Defensin genes in SARS-CoV-2 infection. medRxiv https:\/\/doi.org\/10.1101\/2020.09.21.20195537","DOI":"10.1101\/2020.09.21.20195537"},{"key":"630_CR31","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1128\/CMR.00056-05","volume":"19","author":"H Jenssen","year":"2006","unstructured":"Jenssen H, Hamill P, Hancock R (2006) Peptide antimicrobial agents. Clin Microbiol Rev 19:491\u2013511. https:\/\/doi.org\/10.1128\/CMR.00056-05","journal-title":"Clin Microbiol Rev"},{"key":"630_CR32","doi-asserted-by":"publisher","first-page":"S223","DOI":"10.1097\/01.inf.0000188166.17324.60","volume":"24","author":"JS Kahn","year":"2005","unstructured":"Kahn JS, McIntosh K (2005) History and recent advances in coronavirus discovery. Pediatr Infect Dis J 24:S223\u2013S227. https:\/\/doi.org\/10.1097\/01.inf.0000188166.17324.60","journal-title":"Pediatr Infect Dis J"},{"key":"630_CR33","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1002\/jmv.26589","volume":"93","author":"B Kerget","year":"2021","unstructured":"Kerget B, Kerget F, Aksakal A et al (2021) Evaluation of alpha defensin, IL-1 receptor antagonist, and IL-18 levels in COVID-19 patients with macrophage activation syndrome and acute respiratory distress syndrome. J Med Virol 93:2090\u20132098. https:\/\/doi.org\/10.1002\/jmv.26589","journal-title":"J Med Virol"},{"key":"630_CR34","doi-asserted-by":"publisher","first-page":"e00187","DOI":"10.1128\/JCM.00187-20","volume":"58","author":"S Khan","year":"2020","unstructured":"Khan S, Siddique R, Shereen MA et al (2020) Emergence of a novel coronavirus, severe acute respiratory syndrome coronavirus 2: biology and therapeutic options. J Clin Microbiol 58:e00187-e220. https:\/\/doi.org\/10.1128\/JCM.00187-20","journal-title":"J Clin Microbiol"},{"key":"630_CR35","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s12985-018-1035-2","volume":"15","author":"J Kim","year":"2018","unstructured":"Kim J, Yang YL, Jang SH et al (2018) Human \u03b2-defensin 2 plays a regulatory role in innate antiviral immunity and is capable of potentiating the induction of antigenspecific immunity. Virol J 15:124. https:\/\/doi.org\/10.1186\/s12985-018-1035-2","journal-title":"Virol J"},{"key":"630_CR36","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.imbio.2019.05.004","volume":"224","author":"J Kim","year":"2019","unstructured":"Kim J, Yang YL, Jang YS (2019) Human \u03b2-defensin 2 is involved in CCR2-mediated Nod2 signal transduction, leading to activation of the innate immune response in macrophages. Immunobiology 224:502\u2013510. https:\/\/doi.org\/10.1016\/j.imbio.2019.05.004","journal-title":"Immunobiology"},{"key":"630_CR37","doi-asserted-by":"publisher","first-page":"635","DOI":"10.3390\/vaccines8040635","volume":"8","author":"J Kim","year":"2020","unstructured":"Kim J, Yang YL, Jeong Y et al (2020) Conjugation of human beta-defensin 2 to spike protein receptor-binding domain induces antigen-specific protective immunity against middle east respiratory syndrome coronavirus infection in human dipeptidyl peptidase 4 transgenic mice. Vaccines 8:635. https:\/\/doi.org\/10.3390\/vaccines8040635","journal-title":"Vaccines"},{"key":"630_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0023710","volume":"6","author":"J Lang","year":"2011","unstructured":"Lang J, Yang N, Deng J et al (2011) Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans. PLoS ONE 6:e23710. https:\/\/doi.org\/10.1371\/journal.pone.0023710","journal-title":"PLoS ONE"},{"key":"630_CR39","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1038\/ni1248","volume":"6","author":"E Leikina","year":"2005","unstructured":"Leikina E, Delanoe-Ayari H, Melikov K et al (2005) Carbohydrate-binding molecules inhibit viral fusion and entry by crosslinking membrane glycoproteins. Nat Immunol 6:995\u20131001. https:\/\/doi.org\/10.1038\/ni1248","journal-title":"Nat Immunol"},{"key":"630_CR40","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1189\/jlb.0209050","volume":"86","author":"HN Li","year":"2009","unstructured":"Li HN, Barlow PG, Bylund J et al (2009) Secondary necrosis of apoptotic neutrophils induced by the human cathelicidin LL-37 is not proinflammatory to phagocytosing macrophages. J Leukoc Biol 86:891\u2013902. https:\/\/doi.org\/10.1189\/jlb.0209050","journal-title":"J Leukoc Biol"},{"key":"630_CR41","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.106057","volume":"79","author":"K Li","year":"2020","unstructured":"Li K, Tao N, Zheng L et al (2020) LL-37 restored glucocorticoid sensitivity impaired by virus dsRNA in lung. Int Immunopharmacol 79:106057. https:\/\/doi.org\/10.1016\/j.intimp.2019.106057","journal-title":"Int Immunopharmacol"},{"key":"630_CR42","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.cyto.2016.12.015","volume":"92","author":"J Lyu","year":"2017","unstructured":"Lyu J, Bian T, Chen B et al (2017) Beta-defensin 3 modulates macrophage activation and orientation during acute inflammatory response to Porphyromonas gingivalis lipopolysaccharide. Cytokine 92:48\u201354. https:\/\/doi.org\/10.1016\/j.cyto.2016.12.015","journal-title":"Cytokine"},{"key":"630_CR43","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1164\/rccm.201205-0806OC","volume":"186","author":"P Mallia","year":"2012","unstructured":"Mallia P, Footitt J, Sotero R et al (2012) Rhinovirus Infection induces degradation of antimicrobial peptides and secondary bacterial infection in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 186:1117\u20131124. https:\/\/doi.org\/10.1164\/rccm.201205-0806OC","journal-title":"Am J Respir Crit Care Med"},{"key":"630_CR44","doi-asserted-by":"publisher","first-page":"3361","DOI":"10.3390\/nu12113361","volume":"12","author":"J Mercola","year":"2020","unstructured":"Mercola J, Grant W, Wagner C (2020) Evidence regarding vitamin D and risk of COVID-19 and its severity. Nutrients 12:3361. https:\/\/doi.org\/10.3390\/nu12113361","journal-title":"Nutrients"},{"key":"630_CR45","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.107364","volume":"93","author":"L Mohamed Khosroshahi","year":"2021","unstructured":"Mohamed Khosroshahi L, Rokni M, Mokhtari T et al (2021) Immunology, immunopathogenesis and immunotherapeutics of COVID-19; an overview. Int Immunopharmacol 93:107364. https:\/\/doi.org\/10.1016\/j.intimp.2020.107364","journal-title":"Int Immunopharmacol"},{"key":"630_CR46","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.4049\/jimmunol.176.4.2455","volume":"176","author":"N Mookherjee","year":"2006","unstructured":"Mookherjee N, Brown KL, Bowdish DM et al (2006) Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J Immunol 176:2455\u20132464. https:\/\/doi.org\/10.4049\/jimmunol.176.4.2455","journal-title":"J Immunol"},{"key":"630_CR47","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/s41573-019-0058-8","volume":"19","author":"N Mookherjee","year":"2020","unstructured":"Mookherjee N, Anderson M, Haagsman H et al (2020) Antimicrobial host defence peptides: functions and clinical potential. Nat Rev Drug Discov 19:311\u2013332. https:\/\/doi.org\/10.1038\/s41573-019-0058-8","journal-title":"Nat Rev Drug Discov"},{"key":"630_CR48","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1039\/b813787k","volume":"5","author":"N Mookherjee","year":"2009","unstructured":"Mookherjee N, Hamill P, Gardy J et al (2009) Systems biology evaluation of immune responses induced by human host defence peptide LL-37 in mononuclear cells. Mol Biosyst 5:483\u2013496. https:\/\/doi.org\/10.1039\/b813787k","journal-title":"Mol Biosyst"},{"key":"630_CR49","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.1128\/JVI.02471-09","volume":"84","author":"E Nguyen","year":"2010","unstructured":"Nguyen E, Nemerow G, Smith J (2010) Direct evidence from single-cell analysis that human -defensins block adenovirus uncoating to neutralize infection. J Virol 84:4041\u20134049. https:\/\/doi.org\/10.1128\/JVI.02471-09","journal-title":"J Virol"},{"key":"630_CR50","doi-asserted-by":"publisher","first-page":"5788","DOI":"10.4049\/jimmunol.0901491","volume":"183","author":"A Nijnik","year":"2009","unstructured":"Nijnik A, Pistolic J, Wyatt A et al (2009) Human cathelicidin peptide LL-37 modulates the effects of IFN-gamma on APCs. J Immunol 183:5788\u20135798. https:\/\/doi.org\/10.4049\/jimmunol.0901491","journal-title":"J Immunol"},{"key":"630_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.mehy.2020.110244","volume":"143","author":"Y Niv","year":"2020","unstructured":"Niv Y (2020) Defensin 5 for prevention of SARS-CoV-2 invasion and Covid-19 disease. Med Hypotheses 143:110244. https:\/\/doi.org\/10.1016\/j.mehy.2020.110244","journal-title":"Med Hypotheses"},{"key":"630_CR52","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s40618-020-01327-0","volume":"44","author":"F Panfili","year":"2021","unstructured":"Panfili F, Roversi M, Argenio P et al (2021) Possible role of vitamin D in Covid-19 infection in pediatric population. J Endocrinol Invest 44:27\u201335. https:\/\/doi.org\/10.1007\/s40618-020-01327-0","journal-title":"J Endocrinol Invest"},{"key":"630_CR53","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.jiph.2020.12.020","volume":"14","author":"P Parthasarathy","year":"2020","unstructured":"Parthasarathy P, Vivekanandan S (2020) An extensive study on the COVID-19 pandemic, an emerging global crisis: Risks, transmission, impacts and mitigation. J Infect Public Health 14:249\u2013259. https:\/\/doi.org\/10.1016\/j.jiph.2020.12.020","journal-title":"J Infect Public Health"},{"key":"630_CR54","doi-asserted-by":"publisher","first-page":"155","DOI":"10.14336\/AD.2020.1124","volume":"12","author":"Y Peng","year":"2021","unstructured":"Peng Y, Tao H, Satyanarayanan SK et al (2021) A comprehensive summary of the knowledge on COVID-19 treatment. Aging Dis 12:155\u2013191","journal-title":"Aging Dis"},{"key":"630_CR55","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1038\/icb.2008.56","volume":"86","author":"LC Pingel","year":"2008","unstructured":"Pingel LC, Kohlgraf KG, Hansen CJ et al (2008) Human beta-defensin 3 binds to hemagglutinin B (rHagB), a non-fimbrial adhesin from Porphyromonas gingivalis, and attenuates a pro-inflammatory cytokine response. Immunol Cell Biol 86:643\u2013649. https:\/\/doi.org\/10.1038\/icb.2008.56","journal-title":"Immunol Cell Biol"},{"key":"630_CR56","first-page":"139","volume":"7","author":"E Poveda","year":"2005","unstructured":"Poveda E, Briz V, Soriano V (2005) Enfuvirtide, the first fusion inhibitor to treat HIV infection. AIDS Rev 7:139\u2013147","journal-title":"AIDS Rev"},{"key":"630_CR57","doi-asserted-by":"publisher","unstructured":"Ramadan N, Shaib H (2019) Middle East respiratory syndrome coronavirus (MERS-CoV): A review. Germs 9:35\u201342. https:\/\/doi.org\/10.18683\/germs.2019.1155","DOI":"10.18683\/germs.2019.1155"},{"key":"630_CR58","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s13205-021-02657-3","volume":"11","author":"YK Ratre","year":"2021","unstructured":"Ratre YK, Kahar N, Bhaskar L et al (2021) Molecular mechanism, diagnosis, and potential treatment for novel coronavirus (COVID-19): a current literature review and perspective. 3 Biotech 11:94. https:\/\/doi.org\/10.1007\/s13205-021-02657-3","journal-title":"3 Biotech"},{"key":"630_CR59","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/1471-2172-6-2","volume":"6","author":"R Reghunathan","year":"2005","unstructured":"Reghunathan R, Jayapal M, Hsu LY et al (2005) Expression profile of immune response genes in patients with Severe Acute Respiratory Syndrome. BMC Immunol 6:2. https:\/\/doi.org\/10.1186\/1471-2172-6-2","journal-title":"BMC Immunol"},{"key":"630_CR60","doi-asserted-by":"publisher","first-page":"1138","DOI":"10.2174\/1381612824666180327162357","volume":"24","author":"B Rivas-Santiago","year":"2018","unstructured":"Rivas-Santiago B, Torres-Juarez F (2018) Antimicrobial peptides for the treatment of pulmonary tuberculosis, allies or foes? Curr Pharm Des 24:1138\u20131147. https:\/\/doi.org\/10.2174\/1381612824666180327162357","journal-title":"Curr Pharm Des"},{"key":"630_CR61","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1189\/jlb.0209079","volume":"90","author":"L Ryan","year":"2011","unstructured":"Ryan L, Dai J, Yin Z et al (2011) Modulation of human \u03b2-defensin-1 (hBD-1) in plasmacytoid dendritic cells (PDC), monocytes, and epithelial cells by influenza virus, Herpes simplex virus, and Sendai virus and its possible role in innate immunity. J Leukoc Biol 90:343\u2013356. https:\/\/doi.org\/10.1189\/jlb.0209079","journal-title":"J Leukoc Biol"},{"key":"630_CR62","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1055\/s-0031-1296637","volume":"57","author":"G Salamov","year":"2007","unstructured":"Salamov G, Holms R, Bessler WG et al (2007) Treatment of hepatitis C virus infection with human ezrin peptide one (HEP1) in HIV infected patients. Arzneimittelforschung 57:497\u2013504. https:\/\/doi.org\/10.1055\/s-0031-1296637","journal-title":"Arzneimittelforschung"},{"key":"630_CR63","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1086\/521027","volume":"196","author":"M Salvatore","year":"2007","unstructured":"Salvatore M, Garc\u00eda-Sastre A, Ruchala P et al (2007) alpha-Defensin inhibits influenza virus replication by cell-mediated mechanism(s). J Infect Dis 196:835\u2013843. https:\/\/doi.org\/10.1086\/521027","journal-title":"J Infect Dis"},{"key":"630_CR64","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1183\/13993003.00665-2015","volume":"47","author":"A Sch\u00f6gler","year":"2016","unstructured":"Sch\u00f6gler A, Muster R, Kieninger E et al (2016) Vitamin D represses rhinovirus replication in cystic fibrosis cells by inducing LL-37. Eur Respir J 47:520\u2013530. https:\/\/doi.org\/10.1183\/13993003.00665-2015","journal-title":"Eur Respir J"},{"key":"630_CR65","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.addr.2020.11.007","volume":"167","author":"D Sch\u00fctz","year":"2020","unstructured":"Sch\u00fctz D, Ruiz-Blanco Y, M\u00fcnch J et al (2020) Peptide and peptide-based inhibitors of SARS-CoV-2 entry. Adv Drug Deliv Rev 167:47\u201365. https:\/\/doi.org\/10.1016\/j.addr.2020.11.007","journal-title":"Adv Drug Deliv Rev"},{"key":"630_CR66","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1002\/eji.200940041","volume":"40","author":"F Semple","year":"2010","unstructured":"Semple F, Webb S, Li HN et al (2010) Human beta-defensin 3 has immunosuppressive activity in vitro and in vivo. Eur J Immunol 40:1073\u20131078. https:\/\/doi.org\/10.1002\/eji.200940041","journal-title":"Eur J Immunol"},{"key":"630_CR67","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.4049\/jimmunol.179.2.1245","volume":"179","author":"J Shi","year":"2007","unstructured":"Shi J, Aono S, Lu W et al (2007) A novel role for defensins in intestinal homeostasis: regulation of IL-1beta secretion. J Immunol 179:1245\u20131253. https:\/\/doi.org\/10.4049\/jimmunol.179.2.1245","journal-title":"J Immunol"},{"key":"630_CR68","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.chom.2007.12.001","volume":"3","author":"J Smith","year":"2008","unstructured":"Smith J, Nemerow G (2008) Mechanism of Adenovirus neutralization by human a-defensins. Cell Host Microbe 3:11\u201319. https:\/\/doi.org\/10.1016\/j.chom.2007.12.001","journal-title":"Cell Host Microbe"},{"key":"630_CR69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000959","volume":"6","author":"J Smith","year":"2010","unstructured":"Smith J, Silvestry M, Lindert S et al (2010) Insight into the mechanisms of adenovirus capsid disassembly from studies of defensin neutralization. PLoS Pathog 6:e1000959. https:\/\/doi.org\/10.1371\/journal.ppat.1000959","journal-title":"PLoS Pathog"},{"key":"630_CR70","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.peptides.2017.07.013","volume":"95","author":"FH Sousa","year":"2017","unstructured":"Sousa FH, Casanova V, Findlay F et al (2017) Cathelicidins display conserved direct antiviral activity towards rhinovirus. Peptides 95:76\u201383. https:\/\/doi.org\/10.1016\/j.peptides.2017.07.013","journal-title":"Peptides"},{"key":"630_CR71","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pmed.0030343","volume":"3","author":"L Stockman","year":"2006","unstructured":"Stockman L, Bellamy R, Garner P (2006) SARS: systematic review of treatment effects. PLoS Med 3:e343. https:\/\/doi.org\/10.1371\/journal.pmed.0030343","journal-title":"PLoS Med"},{"key":"630_CR72","doi-asserted-by":"publisher","first-page":"8046","DOI":"10.4049\/jimmunol.178.12.8046","volume":"178","author":"T Tecle","year":"2007","unstructured":"Tecle T, White M, Gantz D et al (2007) Human neutrophil defensins increase neutrophil uptake of influenza A virus and bacteria and modify virus-induced respiratory burst responses. J Immunol 178:8046\u20138052. https:\/\/doi.org\/10.4049\/jimmunol.178.12.8046","journal-title":"J Immunol"},{"key":"630_CR73","doi-asserted-by":"publisher","first-page":"4495","DOI":"10.1128\/IAI.00936-15","volume":"83","author":"F Torres-Juarez","year":"2015","unstructured":"Torres-Juarez F, Cardenas-Vargas A, Montoya-Rosales A et al (2015) LL-37 immunomodulatory activity during Mycobacterium tuberculosis infection in macrophages. Infect Immun 83:4495\u20134503. https:\/\/doi.org\/10.1128\/IAI.00936-15","journal-title":"Infect Immun"},{"issue":"Pt 1","key":"630_CR74","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1099\/vir.0.045013-0","volume":"94","author":"S Tripathi","year":"2013","unstructured":"Tripathi S, Tecle T, Verma A et al (2013) The human cathelicidin LL-37 inhibits influenza A viruses through a mechanism distinct from that of surfactant protein D or defensins. J General Virol 94(Pt 1):40\u201349. https:\/\/doi.org\/10.1099\/vir.0.045013-0","journal-title":"J General Virol"},{"key":"630_CR75","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/s0140-6736(66)92364-6","volume":"1","author":"D Tyrrell","year":"1966","unstructured":"Tyrrell D, Bynoe M (1966) Cultivation of viruses from a high proportion of patients with colds. Lancet 1:76\u201377. https:\/\/doi.org\/10.1016\/s0140-6736(66)92364-6","journal-title":"Lancet"},{"key":"630_CR76","doi-asserted-by":"publisher","first-page":"199","DOI":"10.3341\/kjo.2013.27.3.199","volume":"27","author":"E Uchio","year":"2013","unstructured":"Uchio E, Inoue H, Kadonosono K (2013) Anti-adenoviral effects of human cationic antimicrobial protein-18\/LL-37, an Antimicrobial peptide, by quantitative polymerase chain reaction. Korean J Ophthalmol 27:199\u2013203. https:\/\/doi.org\/10.3341\/kjo.2013.27.3.199","journal-title":"Korean J Ophthalmol"},{"key":"630_CR77","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1016\/j.jhep.2013.12.013","volume":"60","author":"JM Vierling","year":"2014","unstructured":"Vierling JM, Davis M, Flamm S et al (2014) Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon\/ribavirin, including prior null response. J Hepatol 60:748\u2013756. https:\/\/doi.org\/10.1016\/j.jhep.2013.12.013","journal-title":"J Hepatol"},{"key":"630_CR78","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1053\/j.gastro.2020.05.015","volume":"159","author":"C Wang","year":"2020","unstructured":"Wang C, Wang S, Li D et al (2020) Human Intestinal Defensin 5 Inhibits SARS-CoV-2 Invasion by Cloaking ACE2. Gastroenterology 159:1145-1147e1144. https:\/\/doi.org\/10.1053\/j.gastro.2020.05.015","journal-title":"Gastroenterology"},{"key":"630_CR79","unstructured":"WHO (2021) https:\/\/www.who.int\/publications\/m\/item\/draftlandscape-of-covid-19-candidate-vaccines"},{"key":"630_CR80","doi-asserted-by":"publisher","first-page":"4965","DOI":"10.1016\/j.jmb.2013.09.038","volume":"425","author":"S Wilson","year":"2013","unstructured":"Wilson S, Wiens M, Smith J (2013) Antiviral mechanisms of human defensins. J Mol Biol 425:4965\u20134980. https:\/\/doi.org\/10.1016\/j.jmb.2013.09.038","journal-title":"J Mol Biol"},{"key":"630_CR81","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006446","volume":"13","author":"SS Wilson","year":"2017","unstructured":"Wilson SS, Bromme BA, Holly MK et al (2017) Alpha-defensin-dependent enhancement of enteric viral infection. PLoS Pathog 13:e1006446. https:\/\/doi.org\/10.1371\/journal.ppat.1006446","journal-title":"PLoS Pathog"},{"key":"630_CR82","doi-asserted-by":"publisher","first-page":"11385","DOI":"10.1128\/JVI.01363-09","volume":"83","author":"CL Wohlford-Lenane","year":"2009","unstructured":"Wohlford-Lenane CL, Meyerholz DK, Perlman S et al (2009) Rhesus theta-defensin prevents death in a mouse model of severe acute respiratory syndrome coronavirus pulmonary disease. J Virol 83:11385\u201311390. https:\/\/doi.org\/10.1128\/JVI.01363-09","journal-title":"J Virol"},{"key":"630_CR83","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/s41586-020-2196-x","volume":"581","author":"R Wolfel","year":"2020","unstructured":"Wolfel R, Corman VM, Guggemos W et al (2020) Virological assessment of hospitalized patients with COVID-2019. Nature 581:465\u2013469. https:\/\/doi.org\/10.1038\/s41586-020-2196-x","journal-title":"Nature"},{"key":"630_CR84","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1016\/j.bbamem.2015.11.003","volume":"1858","author":"D Xhindoli","year":"2016","unstructured":"Xhindoli D, Pacor S, Benincasa M et al (2016) The human cathelicidin LL-37\u2013A pore-forming antibacterial peptide and host-cell modulator. Biochim Biophys Acta 1858:546\u2013566. https:\/\/doi.org\/10.1016\/j.bbamem.2015.11.003","journal-title":"Biochim Biophys Acta"},{"key":"630_CR85","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","volume":"30","author":"S Xia","year":"2020","unstructured":"Xia S, Liu M, Wang C et al (2020) Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion. Cell Res 30:343\u2013355. https:\/\/doi.org\/10.1038\/s41422-020-0305-x","journal-title":"Cell Res"},{"key":"630_CR86","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aav4580","author":"S Xia","year":"2019","unstructured":"Xia S, Yan L, Xu W et al (2019) A pan-coronavirus fusion inhibitor targeting the HR1 domain of human coronavirus spike. Sci Adv. https:\/\/doi.org\/10.1126\/sciadv.aav4580","journal-title":"Sci Adv"},{"key":"630_CR87","doi-asserted-by":"publisher","first-page":"12703","DOI":"10.1074\/jbc.RA118.003538","volume":"293","author":"D Yu","year":"2018","unstructured":"Yu D, Ding X, Liu Z et al (2018) Molecular mechanism of HIV-1 resistance to sifuvirtide, a clinical trial-approved membrane fusion inhibitor. J Biol Chem 293:12703\u201312718. https:\/\/doi.org\/10.1074\/jbc.RA118.003538","journal-title":"J Biol Chem"},{"key":"630_CR88","doi-asserted-by":"publisher","first-page":"3181","DOI":"10.1002\/eji.200939496","volume":"39","author":"Z Zhang","year":"2009","unstructured":"Zhang Z, Cherryholmes G, Chang F et al (2009) Evidence that cathelicidin peptide LL-37 may act as a functional ligand for CXCR2 on human neutrophils. Eur J Immunol 39:3181\u20133194. https:\/\/doi.org\/10.1002\/eji.200939496","journal-title":"Eur J Immunol"},{"key":"630_CR89","doi-asserted-by":"publisher","first-page":"22008","DOI":"10.1038\/srep22008","volume":"6","author":"H Zhao","year":"2016","unstructured":"Zhao H, Zhou J, Zhang K et al (2016) A novel peptide with potent and broad-spectrum antiviral activities against multiple respiratory viruses. Sci Rep 6:22008. https:\/\/doi.org\/10.1038\/srep22008","journal-title":"Sci Rep"},{"key":"630_CR90","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41423-020-0402-2","volume":"17","author":"M Zheng","year":"2020","unstructured":"Zheng M, Gao Y, Wang G et al (2020) Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cell Mol Immunol 17:533\u2013535. https:\/\/doi.org\/10.1038\/s41423-020-0402-2","journal-title":"Cell Mol Immunol"},{"key":"630_CR91","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.antiviral.2011.07.014","volume":"92","author":"OP Zhirnov","year":"2011","unstructured":"Zhirnov OP, Klenk HD, Wright PF (2011) Aprotinin and similar protease inhibitors as drugs against influenza. Antiviral Res 92:27\u201336. https:\/\/doi.org\/10.1016\/j.antiviral.2011.07.014","journal-title":"Antiviral Res"}],"container-title":["Archivum Immunologiae et Therapiae Experimentalis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00005-021-00630-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00005-021-00630-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00005-021-00630-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,2]],"date-time":"2024-01-02T20:49:36Z","timestamp":1704228576000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00005-021-00630-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,16]]},"references-count":91,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["630"],"URL":"https:\/\/doi.org\/10.1007\/s00005-021-00630-9","relation":{},"ISSN":["0004-069X","1661-4917"],"issn-type":[{"value":"0004-069X","type":"print"},{"value":"1661-4917","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,16]]},"assertion":[{"value":"12 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This content has been made available to all.","name":"free","label":"Free to read"}],"article-number":"25"}}